HB Wealth Management’s CervoMed CRVO Stock Holding History

HB Wealth Management’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-133	Closed	-$3K	–	596
2021 Q4	$3K	Buy	+133	New	+$4.16K	﹤0.01%	520

Other funds holding CRVO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

HB Wealth Management's CRVO Position: Q1 2022 in Review

HB Wealth Management sold out of CervoMed (CRVO) in Q1 2022, closing a stake of 133 shares — an estimated $3K sold.

HB Wealth Management first reported a position in CRVO in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 19 funds tracked by Wall St. Rank hold CRVO as of Q1 2022.

HB Wealth Management reported no remaining CervoMed position as of Q1 2022 after selling out during the quarter.
HB Wealth Management sold 133 CervoMed shares in Q1 2022, an estimated $3K.
HB Wealth Management first reported a position in CervoMed in Q4 2021 and held it in 1 quarter.
HB Wealth Management's CervoMed position peaked at $3K in Q4 2021.
19 funds tracked by Wall St. Rank held CervoMed as of Q1 2022.

Based on HB Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.